Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the…


Previous articlePT247 – Julian Vayne – Magic, Prohibition, and New Models for Legality
Next articleAwakn Life Sciences Completes Previously Announced Private Placement For Gross Proceeds Of $8.3 Million